$Calliditas Therapeutics(CALT.US)$ NEWS Calliditas Announces Positive NefIgArd Open Label Extension Results Calliditas Therapeutics AB announced positive results from the NefIgArd Open Label Extension study, showing consistent treatment response in terms of proteinuria reduction and eGFR stabilization at 9 months for all IgAN patients. The study followed the successful Phase 3 NefIgArd study, which led to FDA approval in December 2023, and the full data set was published in The Lancet. CEO Renée...
$Calliditas Therapeutics(CALT.US)$ NEWS Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 Consistent improvement in estimated glomerular filtrate rate (eGFR) with Nefecon treatment compared to placebo. 30% reduction in UPCR with Nefecon sustained over 2 years, leading to lower risk of kidney failure. Significantly delayed time to kidney function decline events with Nefecon c...
The full approval of TARPEYO by the FDA is seen as a significant achievement for Calliditas, potentially paving the way for future successes. The company's projected revenue growth for 2024 indicates optimism about its financial performance.
CEO Renée Aguiar-Lucander credits successful debt refinancing, a strengthened US leadership team, and TARPEYO's US approval for the company's performance in 2023. Foresees potential for more growth and profitability in the rare disease space in 2024.
Calliditas Therapeutics股票讨论区
NEWS
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB announced positive results from the NefIgArd Open Label Extension study, showing consistent treatment response in terms of proteinuria reduction and eGFR stabilization at 9 months for all IgAN patients. The study followed the successful Phase 3 NefIgArd study, which led to FDA approval in December 2023, and the full data set was published in The Lancet. CEO Renée...
NEWS
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Consistent improvement in estimated glomerular filtrate rate (eGFR) with Nefecon treatment compared to placebo.
30% reduction in UPCR with Nefecon sustained over 2 years, leading to lower risk of kidney failure.
Significantly delayed time to kidney function decline events with Nefecon c...
New article
📊⚡️📊
News
暂无评论